TY - JOUR
T1 - Comparing lesion and feature selections to predict progression in newly diagnosed DLBCL patients with FDG PET/CT radiomics features
AU - Eertink, Jakoba J.
AU - Zwezerijnen, Gerben J. C.
AU - Cysouw, Matthijs C. F.
AU - Wiegers, Sanne E.
AU - Pfaehler, Elisabeth A. G.
AU - Lugtenburg, Pieternella J.
AU - van der Holt, Bronno
AU - Hoekstra, Otto S.
AU - de Vet, Henrica C. W.
AU - Zijlstra, Josee M.
AU - Boellaard, Ronald
N1 - Funding Information: This work is financially supported by the Dutch Cancer Society (# VU 2018–11648). Funding Information: JJE, MCFC, GJCZ, SEW, EAGP, BvdH, HCWdV, OSH, and RB declare no competing financial interests. PJL received research funding from Takeda, Servier, and Roche and received honoraria for advisory boards from Takeda, Servier, Genentech, Genmab, Celgene, and Incyte. JMZ received research funding from Roche and received honoraria for advisory boards from Takeda, Gilead, and Roche. Publisher Copyright: © 2022, The Author(s).
PY - 2022/11
Y1 - 2022/11
N2 - Purpose: Biomarkers that can accurately predict outcome in DLBCL patients are urgently needed. Radiomics features extracted from baseline [18F]-FDG PET/CT scans have shown promising results. This study aims to investigate which lesion- and feature-selection approaches/methods resulted in the best prediction of progression after 2 years. Methods: A total of 296 patients were included. 485 radiomics features (n = 5 conventional PET, n = 22 morphology, n = 50 intensity, n = 408 texture) were extracted for all individual lesions and at patient level, where all lesions were aggregated into one VOI. 18 features quantifying dissemination were extracted at patient level. Several lesion selection approaches were tested (largest or hottest lesion, patient level [all with/without dissemination], maximum or median of all lesions) and compared to the predictive value of our previously published model. Several data reduction methods were applied (principal component analysis, recursive feature elimination (RFE), factor analysis, and univariate selection). The predictive value of all models was tested using a fivefold cross-validation approach with 50 repeats with and without oversampling, yielding the mean cross-validated AUC (CV-AUC). Additionally, the relative importance of individual radiomics features was determined. Results: Models with conventional PET and dissemination features showed the highest predictive value (CV-AUC: 0.72–0.75). Dissemination features had the highest relative importance in these models. No lesion selection approach showed significantly higher predictive value compared to our previous model. Oversampling combined with RFE resulted in highest CV-AUCs. Conclusion: Regardless of the applied lesion selection or feature selection approach and feature reduction methods, patient level conventional PET features and dissemination features have the highest predictive value. Trial registration number and date: EudraCT: 2006–005174-42, 01–08-2008.
AB - Purpose: Biomarkers that can accurately predict outcome in DLBCL patients are urgently needed. Radiomics features extracted from baseline [18F]-FDG PET/CT scans have shown promising results. This study aims to investigate which lesion- and feature-selection approaches/methods resulted in the best prediction of progression after 2 years. Methods: A total of 296 patients were included. 485 radiomics features (n = 5 conventional PET, n = 22 morphology, n = 50 intensity, n = 408 texture) were extracted for all individual lesions and at patient level, where all lesions were aggregated into one VOI. 18 features quantifying dissemination were extracted at patient level. Several lesion selection approaches were tested (largest or hottest lesion, patient level [all with/without dissemination], maximum or median of all lesions) and compared to the predictive value of our previously published model. Several data reduction methods were applied (principal component analysis, recursive feature elimination (RFE), factor analysis, and univariate selection). The predictive value of all models was tested using a fivefold cross-validation approach with 50 repeats with and without oversampling, yielding the mean cross-validated AUC (CV-AUC). Additionally, the relative importance of individual radiomics features was determined. Results: Models with conventional PET and dissemination features showed the highest predictive value (CV-AUC: 0.72–0.75). Dissemination features had the highest relative importance in these models. No lesion selection approach showed significantly higher predictive value compared to our previous model. Oversampling combined with RFE resulted in highest CV-AUCs. Conclusion: Regardless of the applied lesion selection or feature selection approach and feature reduction methods, patient level conventional PET features and dissemination features have the highest predictive value. Trial registration number and date: EudraCT: 2006–005174-42, 01–08-2008.
KW - Diffuse-large-B-cell-lymphoma
KW - F-FDG-PET/CT
KW - Lesion selection
KW - Prediction
KW - Radiomics
UR - http://www.scopus.com/inward/record.url?scp=85135583030&partnerID=8YFLogxK
U2 - https://doi.org/10.1007/s00259-022-05916-4
DO - https://doi.org/10.1007/s00259-022-05916-4
M3 - Article
C2 - 35925442
SN - 1619-7070
VL - 49
SP - 4642
EP - 4651
JO - European journal of nuclear medicine and molecular imaging
JF - European journal of nuclear medicine and molecular imaging
IS - 13
ER -